Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
m (→Also known as) |
m (→Also known as) |
||
| Line 9: | Line 9: | ||
==Also known as== | ==Also known as== | ||
| − | AG-221, CC-90007 | + | *'''Code names:''' AG-221, CC-90007 |
| + | *'''Brand name:''' Idhifa | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 02:25, 28 November 2017
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).
Diseases for which it is used
History of changes in FDA indication
- 8/1/2017: Granted FDA regular approval "for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Also known as
- Code names: AG-221, CC-90007
- Brand name: Idhifa